CHRNA4
CHRNA4 (cholinergic receptor nicotinic alpha 4 subunit; also known as BFNC, EBN and EBN1) is a subunit of neuronal nicotinic acetylcholine receptors, which are pentameric, ligand-gated cation channels. It is the most abundant nAChR subtype expressed in the central nervous system. Browse Assay Genie's current range of CHRNA4 research reagents below, or read on for the biology behind the target.
CHRNA4 is a component of neuronal acetylcholine receptors (nAChRs), which function as pentameric, ligand-gated cation channels with high calcium permeability. When acetylcholine binds, the receptor undergoes a marked change in conformation that opens an ion-conducting channel across the plasma membrane. These excitatory receptors mediate fast synaptic transmission in the nervous system and at the neuromuscular junction. Each subunit confers distinct channel properties, including activation, deactivation and desensitisation kinetics, pH sensitivity, cation permeability and binding to allosteric modulators.
The CHRNA4 protein forms heteropentameric receptors with CHRNB2 and CHRNB4, with CHRNA5 and CHRNB3 acting as accessory subunits. It occurs in two major stoichiometries, (CHRNA4)3:(CHRNB2)2 and (CHRNA4)2:(CHRNB2)3, which differ in unitary conductance, calcium permeability, acetylcholine sensitivity and potentiation by divalent cations. Receptors containing this subunit are located at the synaptic cell membrane, where they modulate calcium-dependent signalling pathways and influence the release of neurotransmitters including dopamine, glutamate and GABA. The protein belongs to the ligand-gated ion channel family, acetylcholine receptor subfamily.
The CHRNA4 gene has previously been listed as cholinergic receptor, nicotinic, alpha polypeptide 4, and is placed by HGNC in the group of cholinergic receptor nicotinic subunits. Mutations in the gene cause nocturnal frontal lobe epilepsy type 1, while polymorphisms that protect against nicotine addiction have also been described. Alternative splicing results in multiple transcript variants. Mouse and rat both carry a Chrna4 ortholog.
Mutations in CHRNA4 cause nocturnal frontal lobe epilepsy type 1, making the subunit a focus for studying channel dysfunction in inherited epilepsy.
Polymorphisms in CHRNA4 that protect against nicotine addiction have been described, linking the receptor to dependence biology.
CHRNA4-containing receptors influence release of dopamine, glutamate and GABA and modulate calcium-dependent signalling in the nervous system.
The two CHRNA4:CHRNB2 stoichiometries differ in conductance, calcium permeability and acetylcholine sensitivity, supporting work on subunit composition and channel properties.
CHRNA4 is a subunit of neuronal nicotinic acetylcholine receptors, pentameric ligand-gated cation channels with high calcium permeability. It contributes to synaptic transmission, modulates calcium-dependent signalling and influences release of dopamine, glutamate and GABA. It is the most abundant nAChR subtype in the central nervous system.
CHRNA4 is also known as BFNC, EBN and EBN1, and was previously named cholinergic receptor, nicotinic, alpha 4 (neuronal). It forms heteropentamers with CHRNB2 and CHRNB4, with CHRNA5 and CHRNB3 as accessory subunits. Alternative splicing gives multiple transcript variants.
Mouse and rat each have a Chrna4 ortholog, so rodent models are commonly used for this subunit; check the datasheet of any product for its validated reactivity. In humans, CHRNA4 mutations cause nocturnal frontal lobe epilepsy type 1, and some polymorphisms protect against nicotine addiction.
Other nicotinic acetylcholine receptor subunits and the beta subunits that co-assemble with CHRNA4 in neuronal receptors.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P43681; product specifications from Assay Genie datasheets.